AbbVie Guides FY Adj EPS to $13.87-$14.07, Above Consensus
ABBV sits 36% above its 52-week low of $187.62.
Summary
AbbVie issued FY adjusted EPS guidance of $13.87 to $14.07, a range that likely exceeds current analyst expectations. The company had previously seen 2026 adjusted EPS of $13.91-$14.11, and the updated guidance reflects 14c dilution from the $10.9B Apogee Therapeutics acquisition, partially offset by 10c of overperformance. The guidance provides a concrete earnings target for the year, giving traders a clear benchmark to measure upcoming quarters against. The company is trading near its 52-week high, and this outlook reinforces the growth narrative following strong Q1 results and the Apogee acquisition.
At the time of this announcement, ABBV was trading at $256.01 on NYSE in the Life Sciences sector, with a market capitalization of approximately $454.8B. The 52-week trading range was $187.62 to $267.47. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.